INS and Graves disease: The adverse event rate was in line with the other studies and, interestingly, there was no substantial difference between the two branches in terms of the development of endocrinopathies: two patients were diagnosed with Graves’ disease after AHST, while among insulin-treated patients, two developed Graves’ disease and one developed autoimmune hypothyroidism [55].